1. Why outcomes mean something different in a cash-pay practice
In insurance-billed medicine, outcomes reporting exists because a payer requires it, and the measures are chosen by the payer. In a cash-pay longevity practice there is no such forcing function, so the metrics get chosen for how good they look in a marketing deck.
The useful reframe: your patient is the payer. The only outcomes worth tracking are the ones that answer a question the patient is already asking silently — am I better than when I started, and is this worth continuing to pay for. A metric that does not bear on renewal is a metric you are collecting for yourself.
That also sets the bar for rigour. You are not publishing research and should not present it as though you are. You are showing an individual their own trajectory, honestly, including where it is flat.
2. The four metric families that hold up
Across hormone, weight-management and longevity practice, the measures that survive contact with a sceptical patient fall into four groups.
| Family | Examples | Why it holds up |
|---|---|---|
| Objective clinical | Lab panels over time, body composition, blood pressure, resting heart rate | Measured by an instrument, not by mood. The trend line is the product; a single reading is not. Requires the same panel, same lab and roughly the same interval to mean anything. |
| Patient-reported, instrumented | Validated symptom and quality-of-life scales administered on a fixed schedule | Subjective data becomes trustworthy when the instrument and the cadence are held constant. A standard scale every 30 days beats a free-text “how are you feeling” every visit. |
| Adherence | Doses taken against doses prescribed, visit attendance, refill continuity | The most under-used family, and the most diagnostic. A patient not improving on a protocol they have taken 40% of has not failed the protocol. Without adherence data you cannot tell those two cases apart. |
| Retention and economics | Programme completion, renewal rate, months on protocol, reason for stopping | The only family that is simultaneously a clinical signal and a business signal. Patients who are improving tend to renew; a falling renewal rate is usually an outcomes problem before it is a marketing one. |
3. Metrics that look impressive and mean little
Average change with no denominator. “Our patients lose 18% of body weight” is unfalsifiable without knowing how many started, how many finished, and whether the ones who stopped are in the average. They almost never are, and that is the whole problem — the people for whom it did not work are the people who left.
Single-timepoint biomarkers. One testosterone level tells you about the assay and the morning. Two, taken the same way at a sensible interval, tell you about the patient.
Composite “biological age” scores. Patients find them compelling and they are excellent for engagement, which is a legitimate use. They are not an outcome measure, the methods behind them differ substantially between vendors, and presenting one as clinical proof invites a challenge you cannot answer.
Satisfaction surveys sent to people still enrolled. You are surveying survivors. If you want the honest number, ask the people who stopped, which almost nobody does — and it is the single most informative dataset a cash-pay clinic can collect.
4. What has to be captured at the visit
Every reporting problem in this space is really a capture problem. You cannot report on a trend you recorded as prose in a note.
Structured, not narrative. A weight typed into a paragraph is invisible to any report. The same number in a discrete field is a chart. This is the difference between a system that can show a patient their trajectory and one that cannot, and it is decided at capture time, not reporting time.
Same instrument, same interval. Fix the panel, the scale and the cadence at protocol design, not per visit. Comparability is what makes a trend line mean anything, and it is destroyed by well-intentioned per-patient variation.
Adherence collected passively. Asking a patient at a visit whether they took their doses produces an optimistic number, reliably. Adherence has to be logged as it happens — a daily check-in the patient marks off, or refill timing as a proxy — or the data is not worth having.
A recorded reason for stopping. One structured field, captured when someone discontinues. It is the highest-value data point in the whole system and the one most clinics never collect.
5. Reporting to the patient vs reporting to yourself
These are different products and conflating them is why most clinic reporting satisfies neither.
To the patient, monthly or at each visit: their own trend on two or three measures they understand, their adherence, and a plain-language read of what changed. The purpose is to make an invisible change visible so a renewal decision is informed rather than emotional. Include the flat lines — a patient who spots you only ever show the good chart stops believing the good chart.
To yourself, quarterly and in aggregate: outcomes by protocol, by provider, and by cohort. Which protocols produce change, which produce change only in adherent patients, where people drop off, and what they say when they leave. This is the reporting that changes what you offer, and it is the reporting that almost never gets built because it has no immediate patient-facing payoff.
The honest constraint worth stating: a small practice will not reach statistical significance on any of this, and should not pretend to. Aggregate reporting in a solo clinic is for spotting a pattern worth investigating, not for proving one.
6. Frequently asked questions
What should a longevity clinic measure?
Four families: objective clinical measures tracked as trends rather than single readings; patient-reported symptoms captured with a consistent validated instrument on a fixed cadence; adherence, which is the most under-used and most diagnostic; and retention, including a structured reason for stopping. Anything else is usually marketing.
Is biological age a real outcome measure?
It is a strong engagement tool and a weak outcome measure. Methods differ substantially between vendors, so scores are not comparable across providers, and presenting one as clinical proof invites a challenge you cannot answer. Use it to hold attention, not to evidence a result.
Why does adherence matter more than the outcome?
Because without it you cannot distinguish a protocol that failed from a protocol that was not taken. A patient who did not improve on 40% adherence has not tested the protocol at all, and treating those two cases the same way leads to changing things that were working.
How do I report outcomes to patients without overclaiming?
Show them their own data rather than clinic averages, include the measures that did not move, and state the interval and the instrument. Individual trajectory is honest and is also more persuasive than an aggregate a patient cannot verify.
Can a solo clinic do meaningful outcomes reporting?
Yes, for individual patients — that is where the value is anyway. Aggregate reporting in a small practice will not reach statistical significance and should be treated as a way to spot patterns worth investigating rather than as evidence.